Sanofi-Aventis leads pack of potential Genzyme suitors
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis appears to be favourite to buy-out Genzyme as the troubled US biotech firm's share price soared amid sale rumours on 23 July.